Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products Long, Proven...
-
Company Generates $21.8 Million in First Quarter 2020 Revenues Revises Annual Revenue Guidance for 2020 MALVERN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading...
-
MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development,...
-
MALVERN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) (the “Company”), a high-performing, revenue generating contract development and manufacturing organization, today...
-
Recro Completes Separation of Baudax Bio and Is Now a Pure Play CDMO Business Company Sets Annual Revenue Record; 2019 Revenues of $99.2 Million Company to Host Conference Call Today at 8:00 AM ET ...
-
MALVERN, Pa., March 02, 2020 (GLOBE NEWSWIRE) -- Recro, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO) with integrated solutions for the development,...
-
Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol “REPH” ...
-
Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of “BXRX” Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 ...
-
Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN,...
-
CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100...